Octreotide Market to Garner High Revenues by 2026, Global Industry Outlook, Size, Growth, Share, Analysis by Coherent Market Insights
SEATTLE, April 02, 2021, (PHARMIWEB) — Octreotide is an octapeptide that is similar to natural somatostatin pharmacologically. It is widely used in the treatment of various types of cancer such as diarrhea, and tumors such as carcinoid, pancreatic islet cell tumors, and vasoactive intestinal peptide secreting tumors. Octreotide acetate is also used to treat other medical conditions such as acromegaly where the body produces an excess of growth hormone.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1836
Presence of robust pipeline of drugs in clinical trials is the prime factor fueling market growth. For instance, in 2016, Mario Negri Institute for pharmacological research completed phase 2 clinical trials of its Octreotide LAR in combination with tolvaptan drug for the treatment of autosomal dominant polycystic kidney disease. This disease has an effect on the glomerular rate and total kidney and cystic volume. Octreotide sponsored by Radbound University is in phase 3 clinical trials from 2016. This drug is under clinical trial for the treatment of angiodysplasia, vascular malformations, gastrointestinal hemorrhage, and anemia with Octreotide. Injection Octreotide, sponsored by PVS memorial hospital is in phase 4 clinical trials since 2016. This injection is indicated for the treatment of pancreatic fistula and complications of pancreatoduodenectomy among patients with the soft pancreas. Furthermore, CAM2029 is being tested, currently in phase 2, for acromegaly and neuroendocrine tumors by Camurus AB in collaboration with Novartis AG. Octreotide chloride is the active ingredient for this product.
A growing number of product launches pertaining to novel Octreotide acetate products by major players in the market are projected to drive market growth. For instance, in 2013, Sagent Pharmaceuticals, a U.S.-based biopharmaceutical company, launched its new drug Octreotide acetate, a samatostatin analog. This drug is used to reduce blood levels of IGF-I (soatomedinC) and growth hormone in acromegaly patients who do not adequately respond to or who cannot be treated by surgery, irradiation and bromocriptine mesylate.
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://bit.ly/3mefdNx
The growing prevalence of diseases such as acromegaly and cancer is projected to raise the demand for Octreotide drugs, which in turn is projected to fuel market growth. According to a survey conducted by the National Institute of Health in 2015, over 4 million people suffer from acromegaly in the U.S.
On the other side, lack of research and development for Octreotide acetate for the treatment of children, lactating and pregnant women is a major factor that is expected to hinder the market growth.
North America is expected to hold a dominant position in the Octreotide market owing to the presence of major players and a robust pipeline of products in the region. For instance, Octreotide capsules sponsored by Chaisma Inc.—a biopharmaceutical company based in the U.S.—completed phase 3 clinical trials in 2017 for the treatment of acromegaly. LAR lanreotide sponsored by Memorial Sloan Kettering Cancer Center, based in New York City, is currently in phase 4 clinical trials since 2016. LAR lanreotide is indicated for the treatment of neuroendocrine tumors. The increasing launch of novel drugs is projected to fuel the growth of the Octreotide market in North America. For instance, in 2011 Mylan Pharmaceutical Ltd—a generic and pharmaceuticals specialty company based in the U.S.—launched the generic version of sandostatin i.e. Octreotide acetate injection USP (pre-filled syringes). Octreotide acetate injection USP is used to treat acromegaly. It is also used to inhibit and suppress severe diarrhea, which is associated with metastatic carcinoid tumors and vasoactive intestinal peptide tumors.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/octreotide-market-1836
Europe is projected to show significant growth in the Octreotide market owing to the rising adoption of smart strategies such as strategic mergers and acquisitions among key players. For instance, in 2017, Novartis AG—a Switzerland-based company—acquired Advanced Accelerator Applications, a France-based company—to increase the development of its therapeutics portfolio, which also includes the development of Octreotide to cure oncology.
Key players operating in the Octreotide market include Samarth Pharma Pvt Ltd., Sun Pharmaceuticals Industries Ltd., Neiss Labs Pvt. Ltd., Novartis AG, and Unique Chemical Ltd. Major players in the market are adopting inorganic growth strategies such as mergers and acquisitions, to strengthen their foothold in the global market. For instance, in 2015, Sun Pharmaceutical Industries Ltd.—Mumbai-based company—acquired Ranbaxy laboratories Ltd.—India-based pharmaceutical company—to enhance its productivity and focus on the development of the therapeutic areas, including the development of new drugs of Octreotide acetate. Such as strategic acquisition among key players in the market is expected to create a lucrative environment for the growth of the Octreotide market in the near future.
By Product Type:-
- Octreotide acetate
- Octreotide chloride
- Indium In-111; Octreotide
- LAR Depot Form
- Immediate Release Injection Form
By Distribution Channel:-
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- North America
- Latin America
- Asia Pacific
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire